Meaningful Scientific Innovation in Schizophrenia: Negative Symptoms and the VRFCAT


Watch Knowledge Forum On-Demand

About the Knowledge Forum

Are you seeking meaningful scientific innovation to support quality data for your schizophrenia trial?

Watch this special Knowledge Forum to gain scientific perspectives from pioneers in the Central Nervous System trial world and experts in clinical endpoint solutions:

In a decentralizing, peri-pandemic trial world, schizophrenia research has continued, despite our industry’s mounting challenges: resource constraints, an overabundance of technology, greater data variability, and increased protocol complexity (among many others). So how are sponsors balancing the need to innovate while supporting the data quality of their schizophrenia trials?

This Knowledge Forum features leading schizophrenia scale authors and assessment experts, Dr. Bill Horan, Dr. Brian Kirkpatrick, Dr. Luca Pani, and Dr. Mark Opler, as they share:

  • The validity and value of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT), the Brief Negative Symptoms Scale (BNSS), the Clinical Assessment Interview for Negative Symptoms (CAINS), and the PANSS in schizophrenia research.
  • The future of hybrid studies and the regulatory implications.
  • Foundational clinical endpoint decisions: how these innovations have helped guide sponsors with schizophrenia portfolios.

About the Speakers

Photo of Mark Opler

Mark Opler, PhD, MPH

Chief Research Officer, WCG Clinical Endpoint Solutions

Brian Kirkpatrick, MD, MSPH

Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas

Bill Horan, PhD

Vice President of Clinical Science, WCG Clinical Endpoint Solutions

Bio photo of Luca Pani, MD

Luca Pani, MD

VP, Regulatory Strategy and Market Access Innovation, WCG Clinical Endpoint Solutions